In this issue:
2-year outcomes after TAVR in high-risk patients… … and in patients deemed inoperable
French registry data support TAVR trial findings
Risk benefit ratio clearly in favour of varenicline
Point-of-care genetic testing for antiplatelet treatment
Omega-3 fat
Please login below to download this issue (PDF)